Hovilpri (pritelivir mesylate)

Where it stands

According to the official records, the FDA approved Hovilpri (pritelivir mesylate) on 2026-10-09. The sponsor is Aicuris Anti-Infect and the application is NDA221154. The product is a tablet and is classed as a new medicine, specifically a new molecular entity.

The records do not give the therapeutic area or the approved indication, so this analysis cannot describe the authorized patient population, dosing or conditions of use. Readers should take those from the FDA approval letter and the prescribing information.

The only milestone recorded is the FDA approval itself. The records contain no earlier submission, filing or review milestones.

Regulatory pathway and designations

The product was reviewed in the US under a New Drug Application (NDA221154). It carries two designations: new molecular entity and priority review. An NME is an active moiety the FDA has not previously approved. Priority review is a designation that shortens the FDA's target review goal compared with standard review. It is generally given to products that could offer a significant improvement in the treatment, diagnosis or prevention of a serious condition.

The records do not say which other expedited programs, if any, applied. They also do not give the submission date, so the actual review duration cannot be calculated. No PDUFA goal date is recorded.

The CHMP opinion date is blank. The records therefore show no EU opinion or EU filing for this product, and the entry covers the US region only. This should not be read as a statement about the EU status.

Safety and pharmacovigilance

The records contain no safety data, such as boxed warnings, contraindications, adverse-event profile, REMS requirements or postmarketing commitments. No safety assessment can be made from them.

For any newly approved NME, the usual sources are the FDA-approved labeling, the review documents, and any postmarketing requirements or commitments listed in the approval letter. After launch, safety signals are tracked through routine pharmacovigilance, including adverse-event reporting.

What to watch

The first priority is to obtain the approved labeling and approval letter. These will confirm the indication, the population, any safety language and any postmarketing obligations, none of which are in the records.

Other points to follow are whether the sponsor files in other regions, since the records show no CHMP opinion, and whether the FDA publishes review documents. Launch timing and market access are not covered by the records and should not be inferred.